St Vincent's Hospital Melbourne

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

  NCT07718737· Phase 2/3· Multitude Therapeutics Inc.· Source

• Enrolling by invitation

  Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study

  NCT07197788· Endogenex, Inc.· Source

• Recruiting

  The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis

  NCT07017686· The Bionics Institute of Australia· Source

• Recruiting

  Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy

  NCT07640191· iVEAcare· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Takeda· Source

• Recruiting

  A Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test

  NCT07569913· bioLytical Laboratories· Source

• Recruiting

  AVS Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease

  NCT07510438· Amplitude Vascular Systems, Inc.· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

  NCT07499674· Phase 3· Vergent Bioscience, Inc.· Source

• Enrolling by invitation

  Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)

  NCT07197775· Endogenex, Inc.· Source

• Recruiting

  Performance After Cardiac Ablation in Endurance Athletes for Atrial Fibrillation

  NCT07726056· University Hospital of Leuven Leuven· Source

• Not yet recruiting

  Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

  NCT07225465· Phase 2· St Vincent's Hospital Melbourne· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· Phase 2· Genmab· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· Phase 2/3· AbbVie· Source

• Recruiting

  A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

  NCT07255404· Phase 2· BioNTech SE· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  NCT06953960· Phase 1/2· AbbVie· Source

• Recruiting

  Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  NCT06824168· Phase 2· Daiichi Sankyo· Source

• Enrolling by invitation

  A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

  NCT07038447· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

  NCT06892522· Phase 1/2· AbbVie· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Takeda· Source

• Recruiting

  A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

  NCT06827236· Phase 1/2· BioNTech SE· Source

• Recruiting

  Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

  NCT06714006· Phase 1· PYC Therapeutics· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Gilead Sciences· Source

• Recruiting

  A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  NCT06528301· Phase 1· Umoja Biopharma· Source

• Active, not recruiting

  Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

  NCT06667687· Phase 1· AbbVie· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Supernus Pharmaceuticals, Inc.· Source

• Recruiting

  BMB-101 in Absence Epilepsy and DEE

  NCT06401538· Phase 2· Bright Minds Biosciences Pty Ltd· Source

• Active, not recruiting

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· Phase 3· Genmab· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis

  NCT07612280· Phase 1/2· Jubilant Therapeutics Inc.· Source

• Active, not recruiting

  A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

  NCT06447168· Ipsen· Source

• Recruiting

  Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

  NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  NCT06428019· Phase 3· AbbVie· Source

• Active, not recruiting

  Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

  NCT06449209· Phase 2· BioNTech SE· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Active, not recruiting

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Ivy Brain Tumor Center· Source

• Recruiting

  Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  NCT06500273· Phase 2· Allogene Therapeutics· Source

• Recruiting

  Safety, Pharmacokinetics, and Pharmacodynamics of MTX-101 in Healthy Adults and Patients

  NCT06324604· Phase 1· Mozart Therapeutics Australia Pty Ltd· Source

• Recruiting

  A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

  NCT06372717· Phase 1· Apollo Therapeutics Ltd· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· AbbVie· Source

• Active, not recruiting

  Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

  NCT06267391· Endogenex, Inc.· Source

• Active, not recruiting

  Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06290934· Phase 2· Gilead Sciences· Source

• Active, not recruiting

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· Phase 2· AbbVie· Source

Showing 50 of 120.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma10 recruiting
• Lung cancer9 recruiting
• Epilepsy4 recruiting
• Myelodysplastic syndromes4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Colorectal cancer3 recruiting
• Pancreatic cancer3 recruiting
• Type 2 diabetes3 recruiting
• Acute myeloid leukaemia2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Hepatitis B2 recruiting
• Hepatitis C2 recruiting
• High blood pressure2 recruiting
• Lupus (SLE)2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• HIV1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Sites

  NCT06368466· bioLytical Laboratories· Source

• Completed

  Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

  NCT05954871· Phase 1· Genentech, Inc.· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· GB002, Inc.· Source

• Completed

  Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

  NCT06145048· Phase 2· Vergent Bioscience, Inc.· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

  NCT05989711· Phase 2· Altimmune, Inc.· Source

• Recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

  NCT05667142· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  Evaluation of Hepatitis B Virus (HBV) DNA Test As Point of Care Tool

  NCT05144776· Kirby Institute· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Edgewise Therapeutics, Inc.· Source

• Terminated

  Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

  NCT05427812· Phase 1/2· Ichnos Sciences SA· Source

• Completed

  Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

  NCT04530123· Phase 2· Takeda· Source

• Terminated

  A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

  NCT05346484· Phase 1· Imugene Limited· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04958785· Phase 2· Gilead Sciences· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

  NCT04980482· Phase 2· Arbutus Biopharma Corporation· Source

• Completed

  Hepatocellular Carcinoma Imaging Using PSMA PET/CT

  NCT05095519· Phase 2· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

  NCT05016882· Phase 2· Novo Nordisk A/S· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  SER150 vs Placebo in Diabetic Kidney Disease

  NCT04881123· Phase 2/3· Serodus AS· Source

• Completed

  Safety and Feasibility of a Novel Endoscopic Intervention for the Treatment of Type II Diabetes

  NCT04725890· Endogenex, Inc.· Source

• Terminated

  Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

  NCT04816604· Phase 2· Gossamer Bio USA, Inc.· Source

• Completed

  Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

  NCT04676529· Phase 1/2· Syntara· Source

• Terminated

  Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

  NCT03981211· Kirby Institute· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  Baricitinib in New-onset Type 1 Diabetes

  NCT04774224· Phase 2· St Vincent's Institute of Medical Research· Source

• Completed

  A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

  NCT04536337· Phase 1· Aligos Therapeutics· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Withdrawn

  Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

  NCT05867056· Phase 1· Immunocore Ltd· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion

  NCT04465461· Pulmonx Corporation· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Terminated

  A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

  NCT04082936· Phase 1/2· IGM Biosciences, Inc.· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source

• Completed

  A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740· Phase 2· Ariad Pharmaceuticals· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Terminated

  Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

  NCT03598608· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Pharmacyclics LLC.· Source

• Completed

  Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

  NCT02910583· Phase 2· Pharmacyclics LLC.· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source

• Completed

  A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

  NCT02500407· Phase 1/2· Genentech, Inc.· Source

• Completed

  Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

  NCT01918215· Flinders University· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

• Completed

  A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

  NCT02100722· Stanford University· Source

• Completed

  Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

  NCT00819208· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma37 works · 20 trials
• Systemic sclerosis (scleroderma)34 works · 3 trials
• Hepatitis B7 works · 7 trials